OLEG NODELMAN - 31 Mar 2021 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)

Role
Director
Signature
Oleg Nodelman, individually and as Manager of EcoR1 Capital, LLC and Biotech Opportunity GP, LLC
Issuer symbol
NUVB
Transactions as of
31 Mar 2021
Transactions value $
$4,589,361
Form type
4
Filing time
30 Nov 2021, 17:07:58 UTC
Next filing
02 Nov 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUVB Class A Common Stock Purchase $1.58M +152K +2.3% $10.45* 6.74M 31 Mar 2021 See Notes 2 and 3 F1, F2, F3
transaction NUVB Class A Common Stock Sale $1.58M +152K +15.25% $10.45* 1.15M 31 Mar 2021 See Notes 2 and 4 F1, F2, F4
transaction NUVB Class A Common Stock Purchase $489K +56.6K +0.79% $8.64* 7.2M 31 Jul 2021 See Notes 2 and 3 F1, F2, F3
transaction NUVB Class A Common Stock Sale -$489K -56.6K -4.7% $8.64* 1.15M 31 Jul 2021 See Notes 2 and 4 F1, F2, F4
transaction NUVB Class A Common Stock Purchase $1.25M +163K +2.27% $7.69* 7.36M 24 Nov 2021 See Notes 2 and 3 F2, F3
transaction NUVB Class A Common Stock Purchase $167K +21.8K +1.9% $7.69* 1.17M 24 Nov 2021 See Notes 2 and 4 F2, F4
holding NUVB Class A Common Stock 3.17M 31 Mar 2021 See Notes 2 and 5 F2, F5
holding NUVB Class A Common Stock 2.2M 31 Mar 2021 See Notes 2 and 6 F2, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 EcoR1 Capital Fund, L.P. ("Capital Fund") and EcoR1 Capital Fund Qualified, L.P. ("Qualified Fund") are private investment funds managed by EcoR1 Capital, LLC ("EcoR1") on a parri passu basis. These securities were transferred from Capital Fund to Qualified Fund as part of a periodic rebalancing of the portfolios of the funds.
F2 EcoR1 is the investment adviser to Capital Fund, Qualified Fund and EcoR1 Venture Opportunity Fund, L.P. ("Venture Fund"). EcoR1 is the general partner of Capital Fund and Qualified Fund, and Biotech Opportunity GP, LLC ("Biotech") is the general partner of Venture Fund. Mr. Nodelman is the manager and controlling owner of EcoR1 and Biotech. The funds hold these securities directly for the benefit of their investors. EcoR1 indirectly beneficially owns them as the investment adviser to the funds. Mr. Nodelman indirectly beneficially owns them as the control person of EcoR1. The Reporting Persons disclaim beneficial ownership of such securities except to the extent of their pecuniary interest therein.
F3 Qualified Fund is the record holder of these securities.
F4 Capital Fund is the record holder of these securities.
F5 EcoR1 Panacea Holdings, LLC, which is the owner of record of these securities, is managed by its managing members, Capital Fund, Qualified Fund and Venture Fund. Each of the Reporting Persons may be deemed a beneficial owner of shares held by EcoR1 Panacea Holdings, LLC, but each Reporting Person disclaims beneficial ownership of any such shares except to the extent of its respective pecuniary interest therein.
F6 These securities are held of record by Venture Fund. Biotech indirectly beneficially owns these securities as the general partner of Venture Fund, and Mr. Nodelman indirectly beneficially owns these securities as the control person of Biotech and EcoR1.

Remarks:

The Reporting Persons are filing this Form 4 jointly, but not as a group, and each expressly disclaims membership in a group within the meaning of Rule 13d-5(b) under the Securities Exchange Act of 1934, as amended. Mr. Nodelman serves on the board of directors of the issuer.